Drilldown: Medicines
Appearance
Medicines > onset
:
Immediate intravascular expansion
or
Postprandial glucose effect within days; HbA1c by 12 weeks 
:
Immediate intravascular expansion
or
Postprandial glucose effect within days; HbA1c by 12 weeks 
Use the filters below to narrow your results.
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (2) ·
[[:Category:Crystalloid_IV_fluids|Crystalloid IV fluid]] (1) ·
[[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (2) ·
[[:Category:Electrolyte_replacements|Electrolyte replacement]] (1) ·
[[:Category:Incretin_modulators|Incretin pathway modulator]] (2)
None (1) ·
'"`UNIQ--vote-00000086-QINU`"' Calcium content is a relative contraindication for co-administration with citrated blood products through the same line'"`UNIQ--ref-00000087-QINU`"'. (1) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)
Showing below up to 3 results in range #1 to #3.

